EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Testing the Feasibility of a Digital Point of Care Solution for the Trusted Near Real-Time Bidirectional Exchange of Novel and Informative Adverse Event Information

Greg Powell, Vijay Kara, Daniel Naranjo, Mangesh Kulkarni, Kerri Best-Sule, Trinka Coster, Machaon Bonafede, Shruti Gangadhar, Lee Kallenbach, Andrew Bate

Therapeutic Innovation & Regulatory Science · 2025

DOI: 10.1007/s43441-024-00711-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Greg Powell und 9 weiteren Autor:innen. Beteiligte Einrichtung: GSK, 5 Moore Dr, Durham, NC, USA. gregory.e.powell@gsk.com. Hauptthemen laut MEDLINE: Pharmacovigilance, Feasibility Studies, Electronic Health Records, Point-of-Care Systems. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A digital point-of-care solution was implemented to test the feasibility of near-real-time bi-directional communication between pharmacovigilance experts (PVEs) and healthcare professionals (HCPs) for exchanging unique and informative adverse event (AE) information. The solution was implemented in a commercially available electronic health record (EHR) system/platform, no direct contact between PVEs and the HCPs was possible. The Clinical Affairs team of the EHR vendor was used as an intermediary to ensure appropriate information was exchanged while protecting HCP and patient privacy. The study yielded 9 drug-event pairs of interest (AEI), 2 of which were confirmed as AEs by the HCP. On average it took 20.6 h to receive initial AEI information and 58.8 h to receive follow-up information, which represents a 96% reduction in time compared to current methods. Both interactions provided unique data that would not have been collected otherwise leading to the PVE being able to appropriately determine a potential causal association. This study successfully demonstrated the feasibility of using a compliant, bi-directional, digitally enabled clinical communication channel at the point of care to complement existing pharmacovigilance activities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceFeasibility StudiesElectronic Health RecordsPoint-of-Care SystemsAdverse Drug Reaction Reporting SystemsHumansDrug-Related Side Effects and Adverse ReactionsCommunicationHealth PersonnelTime Factors

Stichwörter der Autor:innen

Adverse drug reactionsAdverse event reportingDigital healthElectronic health recordsReal-world data

Autor:innen und Institutionen

  • GSK, 5 Moore Dr, Durham, NC, USA. gregory.e.powell@gsk.com.
  • GSK, London, UK.
  • GSK, 5 Moore Dr, Durham, NC, USA.
  • Pharmacocybernetics, LLC., Potomac, MD, USA.
  • Veradigm Inc, Chicago, IL, USA.

Förderung

  • GlaxoSmithKline

Zitieren

APA

Powell, G., Kara, V., Naranjo, D., Kulkarni, M., Best-Sule, K., Coster, T., Bonafede, M., Gangadhar, S., Kallenbach, L., & Bate, A. (2025). Testing the Feasibility of a Digital Point of Care Solution for the Trusted Near Real-Time Bidirectional Exchange of Novel and Informative Adverse Event Information. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00711-9

Vancouver

Powell G, Kara V, Naranjo D, Kulkarni M, Best-Sule K, Coster T, et al. Testing the Feasibility of a Digital Point of Care Solution for the Trusted Near Real-Time Bidirectional Exchange of Novel and Informative Adverse Event Information. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-024-00711-9

BibTeX
@article{Powell2025,
  author = {Powell, Greg and Kara, Vijay and Naranjo, Daniel and Kulkarni, Mangesh and Best-Sule, Kerri and Coster, Trinka and Bonafede, Machaon and Gangadhar, Shruti and Kallenbach, Lee and Bate, Andrew},
  title = {Testing the Feasibility of a Digital Point of Care Solution for the Trusted Near Real-Time Bidirectional Exchange of Novel and Informative Adverse Event Information},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2025},
  doi = {10.1007/s43441-024-00711-9}
}
Kostenlos starten →